← Back to Search

Interferon

IFN-alpha2a for Myeloproliferative Disorder

Phase 2
Waitlist Available
Led By Prithviraj Bose, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is testing if Pegasys can help control the disease in patients with essential thrombocythemia, polycythemia vera, myelofibrosis/myeloid metaplasia, and Philadelphia chromosome-negative chronic myelogenous leukemia. The trial will also study the safety of this treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients with Complete Response (CR) or Partial Response (PR)

Trial Design

1Treatment groups
Experimental Treatment
Group I: IFN-alpha2aExperimental Treatment1 Intervention
Starting dose 90 microgram (mcg) injection under the skin once a week.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IFN-alpha2a
2005
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,962 Previous Clinical Trials
1,803,281 Total Patients Enrolled
Prithviraj Bose, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
11 Total Patients Enrolled
Lucia Masarova, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
189 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are participating in the experiment?

"At this juncture, enrollment in the clinical trial is currently not available. The study began on April 7th 2005 and was revised as recently as August 24th 2022. Likewise, there are 113 trials recruiting participants with myeloproliferative disorders and 34 medical studies using IFN-alpha2a actively enrolling patients."

Answered by AI

What potential side effects have been observed with IFN-alpha2a treatments?

"Although there is not any clinical evidence that IFN-alpha2a is effective, the data in regards to safety suggests a score of 2."

Answered by AI

In what conditions is IFN-alpha2a typically prescribed?

"IFN-alpha2a is a therapeutic agent employed to combat hematological malignancies as well chronic hepatitis b and C, non-Hodgkin's lymphoma, follicular lymphoma."

Answered by AI

Are there still opportunities for people to volunteer for this experiment?

"This research is not currently enrolling patients. It was first posted on April 7th 2005 and underwent its most recent alterations in August 24th 2022. For those looking for other clinical trials, 113 studies related to myeloproliferative disorders are actively enlisting candidates and 34 trials involving IFN-alpha2a are also recruiting volunteers."

Answered by AI

Are there any other investigations which have been conducted with IFN-alpha2a?

"Currently, 34 clinical trials are being conducted for IFN-alpha2a with 11 of them in the advanced phase 3. Buffalo, New york is the epicentre of these studies but there are also many other study centres located across 3486 different sites."

Answered by AI
~4 spots leftby Mar 2025